Alvotech (ALVO)
NASDAQ: ALVOHealth CareBiotechnology: Biological Products (No Diagnostic Substances)USD
At close: Oct 7, 4:00 PM ET · Delayed 15 min
ALVO stock chart
Technical analysisKey statistics
All statistics- Market cap
- $2.09B
- Forward P/E
- 25.62
- EPS (TTM)
- -$0.62
- Dividend yield
- None
- 52-week range
- 2.94 – 9.05
- Day range
- 5.85 – 6.14
- Volume / Avg
- 864.55K / 1.04M
- Beta
- —
- Shares outstanding
- 356.82M
- Next earnings
- Nov 11, 2026
52-week range
ALVO stock today
Shares of Alvotech (ALVO) finished lower on Oct 7 at $5.85, a drop of 4.72% or $0.29 per share, versus the S&P 500's 0.22% decline. At this level, ALVO sits in the middle of its 52-week range of $2.94 to $9.05: 35.3% below the high, set on Oct 15, 2025 and 99.0% above the low. ALVO is up 14.0% year to date, outperforming the S&P 500 (+14.0%). Over the past 12 months, the stock has lost 32.3%.
Alvotech has posted a net loss over the last twelve months (EPS of -$0.62), so its P/E ratio is not meaningful. Alvotech's next earnings report is expected on Nov 11, 2026.
Summary generated from market data by MetaCap's automated system. Methodology
About Alvotech
Company profileAlvotech, through its subsidiaries, develops and manufactures biosimilar medicines for patients worldwide. It offers biosimilar products in the therapeutic areas of autoimmune, eye, and bone disorders, as well as cancer. The company provides AVT02, a high concentration, low-volume adalimumab formulation biosimilar to Humira to treat various inflammatory conditions, including rheumatoid arthritis, psoriatic arthritis, Crohn's disease, ankylosing spondylitis ulcerative colitis, and other indications; AVT04, a biosimilar to Stelara to treat various inflammatory conditions comprising psoriatic arthritis, Crohn's disease, ulcerative colitis, plaque psoriasis, and other indications; AVT06, a biosimilar to Eylea to treat various conditions, such as neovascular age-related macular degeneration, macular edema following retinal vein occlusion, diabetic macular edema and diabetic retinopathy; and AVT03, a biosimilar to Xgeva and Prolia to treat prevent bone fracture, spinal cord compression, and the need for radiation or bone surgery in patients with certain types of cancer, as well as prevent bone loss and increase bone mass.
- Sector
- Health Care
- Industry
- Biotechnology: Biological Products (No Diagnostic Substances)
- CEO
- Ms. Lisa Graver
- Headquarters
- Luxembourg
- Employees
- 1,279
- Website
- alvotech.com
Analyst forecast
ForecastConsensus (7 analysts)
none
Avg. price target
$6.80+16.24%
- Strong buy 2
- Buy 4
- Hold 1
- Sell 0
- Strong sell 0
Target range
Ratings and targets reflect third-party analyst opinions, not MetaCap recommendations.
Earnings
Earnings history- Next report
- Nov 11, 2026
Alvotech peers
Health Care sector| Company | Price | % Chg | Market cap | Compare |
|---|---|---|---|---|
| RXRXRecursion Pharmaceuticals Inc. Class A | 4.27 | -7.78% | $2.29B | vs ALVO |
| ADMAADMA Biologics Inc | 10.14 | -0.39% | $2.27B | vs ALVO |
| BEAMBeam Therapeutics Inc. | 24.77 | -1.82% | $2.56B | vs ALVO |
| BCRXBioCryst Pharmaceuticals Inc. | 8.40 | +5.66% | $2.15B | vs ALVO |
| VCELVericel Corporation | 40.74 | +1.72% | $2.09B | vs ALVO |
| VIRVir Biotechnology Inc. | 11.52 | -0.69% | $1.95B | vs ALVO |
| NVAXNovavax Inc. | 11.22 | -0.88% | $1.85B | vs ALVO |
| MESOMesoblast Limited ADR | 13.94 | +2.42% | $1.81B | vs ALVO |
Indexes, lists and sector
Alvotech stock FAQ
What is Alvotech's stock price today?
ALVO last traded at $5.85 as of Oct 7, 4:00 PM EDT, down 4.72% on the day. Prices are delayed at least 15 minutes.
When is Alvotech's next earnings date?
Alvotech is expected to report earnings on Wednesday, November 11, 2026.
Who is Alvotech's CEO?
Ms. Lisa Graver is the chief executive officer of Alvotech, which has about 1,279 employees.
What is the ALVO 52-week high?
The 52-week high for ALVO is $9.05 and the 52-week low is $2.94. The stock is currently 35.3% below its high.